Biomarin Pharmaceutical Inc (BMRN)

112.00 +3.67  +3.39% NASDAQ Jun 3, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
07/31/2020 16:30 EDT Misc Biomarin Pharmaceutical Inc Second Quarter Earnings Conference Call in 2020
07/31/2020 Earnings Biomarin Pharmaceutical Inc Second Quarter Earnings in 2020 Release
05/27/2020 09:00 PDT Misc Biomarin Pharmaceutical Inc Annual General Meeting for 2019
04/30/2020 16:30 EDT Misc Biomarin Pharmaceutical Inc First Quarter Earnings Conference Call for 2020
04/30/2020 Earnings Biomarin Pharmaceutical Inc First Quarter Earnings Result for 2020
02/27/2020 Misc Biomarin Pharmaceutical Inc Annual Report for 2019
02/26/2020 16:30 EST Misc Biomarin Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 2019
02/26/2020 Earnings Biomarin Pharmaceutical Inc Fourth Quarter Earnings in 2019 Release
10/23/2019 16:30 EDT Misc Biomarin Pharmaceutical Inc Third Quarter Earnings Conference Call for 2019
10/23/2019 Earnings Biomarin Pharmaceutical Inc Third Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.bmrn.com
  • Investor Relations URL: http://investors.bmrn.com/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Jul. 31, 2020
  • Last Earnings Release: Apr. 30, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Top Fund Holders

Symbol Name Weighting
BBH VanEck Vectors Biotech ETF 4.57%
FBT First Trust NYSE Arca Biotech ETF 3.67%
VHCOX Vanguard Capital Opportunity Inv 3.26%
POAGX PRIMECAP Odyssey Aggressive Growth 2.19%
XBI SPDR® S&P Biotech ETF 2.15%
IBB iShares Nasdaq Biotechnology ETF 2.10%
POGRX PRIMECAP Odyssey Growth 2.00%
FXH First Trust Health Care AlphaDEX® ETF 1.80%
RAEBX American Funds AMCAP R2E 1.56%
FBIOX Fidelity® Select Biotechnology 1.45%
VEXMX Vanguard Extended Market Index Investor 0.39%
VXF Vanguard Extended Market ETF 0.39%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.